Literature DB >> 32424643

How do prostate cancer patients navigate the active surveillance journey? A 3-year longitudinal study.

Paola Dordoni1, Fabio Badenchini2, Maria Francesca Alvisi2, Julia Menichetti3, Letizia De Luca2, Teresa Di Florio2, Tiziana Magnani2, Cristina Marenghi2, Tiziana Rancati2, Riccardo Valdagni2,4,5, Lara Bellardita2.   

Abstract

OBJECTIVE: To investigate whether prostate cancer (PCa) patients' coping strategies (i.e., fighting spirit, anxious preoccupation, fatalism, helplessness/hopelessness, and avoidance) significantly change during the first 3-year follow-up period of active surveillance (AS).
MATERIALS AND METHODS: Altogether, 104 patients on AS completed the Mini-Mental Adjustment to Cancer (Mini-MAC) at baseline (T0), at 10 and 12 months after diagnostic biopsy (T1 and T2, respectively) and then at 24- (T3) and 36-month (T4) follow-up. Paired samples T test was used to detect statistically significant changes over time. Changes ≥ 1 point (or ≤ - 1) were hypothesized to be clinically relevant.
RESULTS: During the first 3 years on AS, men experienced decreased anxiety, avoidance thoughts/behaviors, and fight-against-cancer attitudes, and these changes were found to be statistically significant. When considering clinically significant changes between inclusion in AS (T0) and 3-year follow-up (T4), avoidance decreased in 19% of patients.
CONCLUSIONS: Most patients were observed to have adopted functional coping strategies at baseline, which were maintained through the first 3 years on AS. Overall, men on AS may perceive increasing control over their cancer and comfort with the AS protocol over time and experience slight decreases in anxious preoccupation, cancer-related avoidance thoughts and behaviors, and fight-against-cancer reactions. For those men who find it difficult to cope with AS, psychological monitoring and interventions could be helpful throughout the monitoring journey.

Entities:  

Keywords:  Active surveillance; Cancer; Coping strategy; Oncology; Prostate cancer

Mesh:

Year:  2020        PMID: 32424643     DOI: 10.1007/s00520-020-05524-8

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  29 in total

1.  Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age.

Authors:  Wolfgang Linden; Andrea Vodermaier; Regina Mackenzie; Duncan Greig
Journal:  J Affect Disord       Date:  2012-06-21       Impact factor: 4.839

Review 2.  Outlook and adaptation in advanced cancer: a systematic review.

Authors:  Charlotte Wattebot O'Brien; Stirling Moorey
Journal:  Psychooncology       Date:  2010-12       Impact factor: 3.894

3.  Development of a questionnaire measure of adjustment to cancer: the MAC scale.

Authors:  M Watson; S Greer; J Young; Q Inayat; C Burgess; B Robertson
Journal:  Psychol Med       Date:  1988-02       Impact factor: 7.723

Review 4.  Conceptual analysis of suffering in cancer: a systematic review.

Authors:  Megan Best; Lynley Aldridge; Phyllis Butow; Ian Olver; Fleur Webster
Journal:  Psychooncology       Date:  2015-03-09       Impact factor: 3.894

Review 5.  Coping with prostate cancer: a meta-analytic review.

Authors:  Scott C Roesch; Linda Adams; Amanda Hines; Alan Palmores; Pearlin Vyas; Cindy Tran; Shannon Pekin; Allison A Vaughn
Journal:  J Behav Med       Date:  2005-06

6.  Empowerment of men newly diagnosed with prostate cancer.

Authors:  B J Davison; L F Degner
Journal:  Cancer Nurs       Date:  1997-06       Impact factor: 2.592

7.  An analysis of coping in a middle-aged community sample.

Authors:  S Folkman; R S Lazarus
Journal:  J Health Soc Behav       Date:  1980-09

8.  Quality of life after radical prostatectomy or watchful waiting.

Authors:  Gunnar Steineck; Fred Helgesen; Jan Adolfsson; Paul W Dickman; Jan-Erik Johansson; Bo Johan Norlén; Lars Holmberg
Journal:  N Engl J Med       Date:  2002-09-12       Impact factor: 91.245

9.  Patients' adjustment to cancer: the Mental Adjustment to Cancer (MAC) scale vs clinical ratings.

Authors:  S Greer; S Moorey; M Watson
Journal:  J Psychosom Res       Date:  1989       Impact factor: 3.006

10.  " The Worst Thing Was…": Prostate Cancer Patients' Evaluations of Their Diagnosis and Treatment Experiences.

Authors:  Christopher F Sharpley; Vicki Bitsika; David R H Christie
Journal:  Am J Mens Health       Date:  2018-04-30
View more
  5 in total

1.  Cross-cultural differences in men on active surveillance' anxiety: a longitudinal comparison between Italian and Dutch patients from the Prostate cancer Research International Active Surveillance study.

Authors:  Paola Dordoni; Sebastiaan Remmers; Riccardo Valdagni; Lara Bellardita; Letizia De Luca; Fabio Badenchini; Cristina Marenghi; Monique J Roobol; Lionne D F Venderbos
Journal:  BMC Urol       Date:  2022-07-18       Impact factor: 2.090

2.  Supporting Patients With Untreated Prostate Cancer on Active Surveillance: What Causes an Increase in Anxiety During the First 10 Months?

Authors:  Maria Francesca Alvisi; Paola Dordoni; Tiziana Rancati; Barbara Avuzzi; Nicola Nicolai; Fabio Badenchini; Letizia De Luca; Tiziana Magnani; Cristina Marenghi; Julia Menichetti; Villa Silvia; Zollo Fabiana; Salvioni Roberto; Valdagni Riccardo; Bellardita Lara
Journal:  Front Psychol       Date:  2020-11-19

3.  Factors that influence clinicians' decisions to decrease active surveillance monitoring frequency or transition to watchful waiting for localised prostate cancer: a qualitative study.

Authors:  Lisa M Lowenstein; Noah J Choi; Karen E Hoffman; Robert J Volk; Stacy Loeb
Journal:  BMJ Open       Date:  2021-11-12       Impact factor: 2.692

Review 4.  Active surveillance for prostate cancer.

Authors:  Daniela K Shill; Monique J Roobol; Behfar Ehdaie; Andrew J Vickers; Sigrid V Carlsson
Journal:  Transl Androl Urol       Date:  2021-06

Review 5.  miRNAs as Therapeutic Tools and Biomarkers for Prostate Cancer.

Authors:  Noemi Arrighetti; Giovanni Luca Beretta
Journal:  Pharmaceutics       Date:  2021-03-13       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.